Liver cirrhosis is a global issue that affects people of all ages, genders, and ethnicities, In the world, it is the 14th most prevalent cause of mortality in adults , ranking 4th in Europe and 9th in theUnited States.
The connections between the gut and liver have given rise to the phrase "gut-liver axis."Thisaxis could be disturbed in decompensated cirrhosis with increase intestinal permeability.
Recent research has identified medications use as one of the most significant contributors to the disruption of the composition of the gut microbiota and gut- liver axis failure. Example of these medications includes proton pump inhibitors (PPIs).
Aim of the work:
The aim of the study was to measure IFABP2 as a diagnostic marker for gut wall integrity in decompensated cirrhosis.Moreover, its relationship with chronic use of PPIs in cirrhosis.
Patients and Methods:
This study was carried out on 75 candidates (32 females & 43 males) at Tropical medicine Department of Alexandria university. Subjects were categorized into 3 groups; group I (n=30) with compensated liver cirrhosis, group II (n=30) with hepatic decompensation which were subdivided into Group IIa (n=15) with chronic use of PPIs and Group IIb(n=15) without chronic use of PPIs, and group III (n=15) healthy controls.IFABP2was measured by ELISA.